Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin.

[1]  F. Carvalho,et al.  Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells. , 2013, Toxicology letters.

[2]  J. Schellens,et al.  Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP , 2012, Investigational New Drugs.

[3]  M. de Lourdes Bastos,et al.  P‐glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[4]  M. X. Fernandes,et al.  New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors , 2011, Chemical biology & drug design.

[5]  Donald W. Miller,et al.  Assessment of P-glycoprotein Activity in the Blood-Brain Barrier (BBB) Using Near Infrared Fluorescence (NIRF) Imaging Techniques , 2011, Pharmaceutical Research.

[6]  G. Levin,et al.  Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine , 2011, Biopharmaceutics & drug disposition.

[7]  F. Carvalho,et al.  In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells , 2011, Archives of Toxicology.

[8]  S. Apte.  Selecting surfactants for the maximum inhibition of the activity of the multidrug resistance efflux pump transporter, P-glycoprotein: conceptual development. , 2010 .

[9]  J. Duarte,et al.  Effect of chronic ethanol exposure on the hepatotoxicity of ecstasy in mice: an ex vivo study. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[10]  C. Hirayama,et al.  Constitutive Overexpression of P-glycoprotein, Rather than Breast Cancer Resistance Protein or Organic Cation Transporter 1, Contributes to Acquisition of Imatinib-Resistance in K562 Cells , 2008, Pharmaceutical Research.

[11]  J. Duarte,et al.  P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. , 2006, Free radical biology & medicine.

[12]  M. Pirmohamed,et al.  Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. , 2006, British journal of clinical pharmacology.

[13]  P. Couraud,et al.  Rat Brain Endothelial Cell Lines for the Study of Blood–Brain Barrier Permeability and Transport Functions , 2005, Cellular and Molecular Neurobiology.

[14]  S. Reis,et al.  Influence of some anti-inflammatory drugs in membrane fluidity studied by fluorescence anisotropy measurementsPresented at the 17th Conference of the European Colloid & Interface Science Society, Firenze, Italy, September 21?26, 2003 , 2004 .

[15]  C. Dey,et al.  P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. , 2003, Pharmacological research.

[16]  D. Begley,et al.  Lipids in blood-brain barrier models in vitro I: Thin-layer chromatography and high-performance liquid chromatography for the analysis of lipid classes and long-chain polyunsaturated fatty acids , 2002, In Vitro Cellular & Developmental Biology - Animal.

[17]  R. Kim.  Drugs as P-glycoprotein substrates, inhibitors, and inducers , 2002, Drug metabolism reviews.

[18]  Maria do Céu Costa,et al.  NMR studies of some rifamycins , 2001 .

[19]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[20]  V. Ling,et al.  Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. , 1997, Biochemical pharmacology.

[21]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[22]  B. Sankaran,et al.  P-glycoprotein Is Stably Inhibited by Vanadate-induced Trapping of Nucleotide at a Single Catalytic Site (*) , 1995, The Journal of Biological Chemistry.

[23]  Y. Assaraf,et al.  Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. , 1995, European journal of biochemistry.

[24]  A. Strosberg,et al.  Regulation of gamma‐glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells , 1994, Journal of cellular physiology.

[25]  D. Lasič,et al.  Liposomes: From Physics to Applications , 1993 .

[26]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[27]  S. Gupta,et al.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. , 1986, The Journal of clinical investigation.

[28]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[29]  W. D. Mcelroy,et al.  Kinetics of the firefly luciferase catalyzed reactions. , 1974, Biochemistry.

[30]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[31]  I. Tucker,et al.  Mechanistic studies of the effect of bile salts on rhodamine 123 uptake into RBE4 cells. , 2012, Molecular pharmaceutics.

[32]  P. Pávek,et al.  Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. , 2010, Methods in molecular biology.

[33]  A. Hilgeroth,et al.  Impact of Novel MDR Modulators on Human Cancer Cells: Reversal Activities and Induction Studies , 2008, Pharmaceutical Research.

[34]  V. Knick,et al.  P-Glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine®) , 2007, Investigational New Drugs.

[35]  G. Decorti,et al.  Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. , 2004, European journal of pharmacology.

[36]  T. Grogan,et al.  P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Lakowicz.  Principles of fluorescence spectroscopy , 1983 .